Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · IEX Real-Time Price · USD
38.73
-1.27 (-3.18%)
At close: Jul 2, 2024, 4:00 PM
39.90
+1.17 (3.02%)
After-hours: Jul 2, 2024, 6:16 PM EDT
Structure Therapeutics Employees
Structure Therapeutics had 93 employees as of December 31, 2023. The number of employees increased by 25 or 36.76% compared to the previous year.
Employees
93
Change (1Y)
25
Growth (1Y)
36.76%
Revenue / Employee
n/a
Profits / Employee
-$1,050,333
Market Cap
2.31B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 93 | 25 | 36.76% |
Dec 31, 2022 | 68 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Integra LifeSciences Holdings | 3,946 |
UFP Technologies | 3,093 |
10x Genomics | 1,259 |
agilon health | 1,117 |
STAAR Surgical Company | 1,115 |
PTC Therapeutics | 995 |
Iovance Biotherapeutics | 557 |
Agios Pharmaceuticals | 386 |
GPCR News
- 25 days ago - Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares - GlobeNewsWire
- 27 days ago - Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - Structure Therapeutics reports promising weight-loss drug data - Invezz
- 4 weeks ago - Structure Therapeutics' stock jumps on weight-loss-pill trial results - Market Watch
- 4 weeks ago - Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 - GlobeNewsWire
- 2 months ago - Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance - CNBC
- 2 months ago - Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates. - Market Watch